Prolonged norovirus infection after pancreas transplantation: A case report and review of chronic norovirus

Transplant Infectious Disease

Volumn 18, Issue 1, 2016, Pages 98-104

  Echenique, I A ^a   Stosor, V ^b   Gallon, L ^b   Kaufman, D ^c   Qi, C ^b,d   Zembower, T R ^b  

^a DEPARTMENT OF COLORECTAL SURGERY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

Chronic diarrhea; Colitis; Diarrhea; End stage renal disease; Gastroenteritis; Norovirus; Organ rejection; Pancreas transplant; Solid organ transplantation

Indexed keywords

ALEMTUZUMAB; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; METRONIDAZOLE; MYCOPHENOLATE MOFETIL; NITAZOXANIDE; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ADULT; ANTIGEN DETECTION; ARTICLE; BACTERIUM CULTURE; CASE REPORT; DISEASE COURSE; END STAGE RENAL DISEASE; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; HEMODIALYSIS; HISTOPATHOLOGY; HUMAN; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVING DONOR; MIDDLE AGED; NOROVIRUS INFECTION; PANCREAS FUNCTION; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REHYDRATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGMOIDOSCOPY; VIRAL CLEARANCE; VIRUS LOAD; CALICIVIRUS INFECTION; CHRONIC DISEASE; CHRONIC KIDNEY FAILURE; COMPLICATION; GASTROENTERITIS; GENETICS; IMMUNOCOMPROMISED PATIENT; ISOLATION AND PURIFICATION; NOROVIRUS; VIROLOGY;

CALICIVIRIDAE INFECTIONS; CHRONIC DISEASE; FEMALE; GASTROENTERITIS; GRAFT REJECTION; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; NOROVIRUS; PANCREAS TRANSPLANTATION;

EID: 84958609674     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12472     Document Type: Article

References (33)

1. Hall AJ, Wikswo ME, Manikonda K, Roberts VA, Yoder JS, Gould LH. Acute gastroenteritis surveillance through the National Outbreak Reporting System, United States. Emerg Infect Dis 2013; 19 (8): 1305-1309.
2. Florescu DF, Hermsen ED, Kwon JY, et al. Is there a role for oral human immunoglobulin in the treatment for norovirus enteritis in immunocompromised patients? Pediatr Transplant 2011; 15 (7): 718-721.
3. Florescu DF, Hill LA, McCartan MA, Grant W. Two cases of Norwalk virus enteritis following small bowel transplantation treated with oral human serum immunoglobulin. Pediatr Transplant 2008; 12 (3): 372-375.
4. Ebdrup L, Bottiger B, Molgaard H, Laursen AL. Devastating diarrhoea in a heart-transplanted patient. J Clin Virol 2011; 50 (4): 263-265.
5. Chagla Z, Quirt J, Woodward K, Neary J, Rutherford C. Chronic norovirus infection in a transplant patient successfully treated with enterally administered immune globulin. J Clin Virol 2013; 58 (1): 306-308.
6. Siddiq DM, Koo HL, Adachi JA, Viola GM. Norovirus gastroenteritis successfully treated with nitazoxanide. J Infect 2011; 63 (5): 394-397.
7. Engelen MA, Gunia S, Stypmann J. Elimination of norovirus in a chronic carrier under immunosuppression after heart transplantation-effect of everolimus. Transplant Int 2011; 24 (11): e102-e103.
8. Bok K, Green KY. Norovirus gastroenteritis in immunocompromised patients. N Engl J Med 2012; 367 (22): 2126-2132.
9. Boillat Blanco N, Kuonen R, Bellini C, et al. Chronic norovirus gastroenteritis in a double hematopoietic stem cell and lung transplant recipient. Transpl Infect Dis 2011; 13 (2): 213-215.
10. Kaufman SS, Chatterjee NK, Fuschino ME, et al. Calicivirus enteritis in an intestinal transplant recipient. Am J Transplant 2003; 3 (6): 764-768.
11. Roos-Weil D, Ambert-Balay K, Lanternier F, et al. Impact of norovirus/sapovirus-related diarrhea in renal transplant recipients hospitalized for diarrhea. Transplantation 2011; 92 (1): 61-69.
12. Zheng DP, Ando T, Fankhauser RL, Beard RS, Glass RI, Monroe SS. Norovirus classification and proposed strain nomenclature. Virology 2006; 346 (2): 312-323.
13. Shirato H, Ogawa S, Ito H, et al. Noroviruses distinguish between type 1 and type 2 histo-blood group antigens for binding. J Virol 2008; 82 (21): 10756-10767.
14. Donaldson EF, Lindesmith LC, Lobue AD, Baric RS. Norovirus pathogenesis: mechanisms of persistence and immune evasion in human populations. Immunol Rev 2008; 225: 190-211.
15. Simmons K, Gambhir M, Leon J, Lopman B. Duration of immunity to norovirus gastroenteritis. Emerg Infectious Dis 2013; 19 (8): 1260-1267.
16. Lindesmith LC, Costantini V, Swanstrom J, et al. Emergence of a norovirus GII.4 strain correlates with changes in evolving blockade epitopes. J Virol 2013; 87 (5): 2803-2813.
17. Schorn R, Hohne M, Meerbach A, et al. Chronic norovirus infection after kidney transplantation: molecular evidence for immune-driven viral evolution. Clin Infect Dis 2010; 51 (3): 307-314.
18. Nilsson M, Hedlund KO, Thorhagen M, et al. Evolution of human calicivirus RNA in vivo: accumulation of mutations in the protruding P2 domain of the capsid leads to structural changes and possibly a new phenotype. J Virol 2003; 77 (24): 13117-13124.
19. Echenique IA, Penugonda S, Stosor V, Ison MG, Angarone MP. Diagnostic yields in solid organ transplant recipients admitted with diarrhea. Clin Infect Dis 2015; 60 (5): 729-737.
20. Lee BE, Pang XL, Robinson JL, Bigam D, Monroe SS, Preiksaitis JK. Chronic norovirus and adenovirus infection in a solid organ transplant recipient. Pediatr Infect Dis J 2008; 27 (4): 360-362.
21. Westhoff TH, Vergoulidou M, Loddenkemper C, et al. Chronic norovirus infection in renal transplant recipients. Nephrol Dial Transplant 2009; 24 (3): 1051-1053.
22. Kandaswamy R, Stock PG, Skeans MA, et al. OPTN/SRTR 2011 Annual Data Report: pancreas. Am J Transplant 2013; 13 (Suppl 1): 47-72.
23. Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006; 81 (9): 1234-1248.
24. Andrassy J, Hoffmann VS, Rentsch M, et al. Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? A systematic review and meta-analysis. Transplantation 2012; 94 (12): 1208-1217.
25. Zaborowska I, Walsh D. PI3K signaling regulates rapamycin-insensitive translation initiation complex formation in vaccinia virus-infected cells. J Virol 2009; 83 (8): 3988-3992.
26. McNulty S, Flint M, Nichol ST, Spiropoulou CF. Host mTORC1 signaling regulates andes virus replication. J Virol 2013; 87 (2): 912-922.
27. Geissler EK. The influence of mTOR inhibitors on immunity and the relationship to post-transplant malignancy. Transplant Res 2013; 2 (Suppl 1): S2.
28. Keating R, Hertz T, Wehenkel M, et al. The kinase mTOR modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus. Nat Immunol 2013; 14 (12): 1266-1276.
29. Weichhart T, Haidinger M, Katholnig K, et al. Inhibition of mTOR blocks the anti-inflammatory effects of glucocorticoids in myeloid immune cells. Blood 2011; 117 (16): 4273-4283.
30. Araki K, Turner AP, Shaffer VO, et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009; 460 (7251): 108-112.
31. Mattison K, Grudeski E, Auk B, et al. Multicenter comparison of two norovirus ORF2-based genotyping protocols. J Clin Microbiol 2009; 47 (12): 3927-3932.
32. Bull RA, Eden JS, Luciani F, McElroy K, Rawlinson WD, White PA. Contribution of intra- and interhost dynamics to norovirus evolution. J Virol 2012; 86 (6): 3219-3229.
33. Siebenga JJ, Beersma MF, Vennema H, van Biezen P, Hartwig NJ, Koopmans M. High prevalence of prolonged norovirus shedding and illness among hospitalized patients: a model for in vivo molecular evolution. J Infect Dis 2008; 198 (7): 994-1001.